Al aceptar estas tecnologas, podremos procesar datos como el comportamiento de navegacin o los identificadores nicos en este sitio web
Disclosures: Oluwaseun Falade-Nwulia: AbbVie Inc: Grant/Research Support, Gilead Sciences: Advisor, Jennifer Price: Nothing to Disclose, Jordan Feld: Mirum: Consultant, AbbVie, Bluejays, Gilead, Janssen, GSK, Roche, VIR Roche: Consultant, Bluejays: Consultant, Gilead: Consultant, Janssen: Consultant, GSK: Consultant, Roche: Consultant, VIR Biotechnology: Consultant, Altimmune, AbbVie, Gilead, Jannsen, GSK, Roche, VIR Bio: Grant/Research Support, Ellen Eaton: Gilead Foundation: Patient Engagement Working Group, Franco Ricardo: Nothing to Disclose, Brittany Barnaba: Pfizer, Inc.: Stock - publicly traded company, Diane Brown: Nothing to Disclose, Sarah Hussain: Nothing to Disclose, Catherine Wren: Nothing to Disclose, Hamidreza Karimi Sari: Nothing to Disclose, Kyoko Hirose: Nothing to Disclose, Chris Cavacuiti: Nothing to Disclose, Stephen O'rear: Nothing to Disclose, Camelia Capraru: Nothing to Disclose, Karin Tobin: Nothing to Disclose, Sheree Schwartz: Nothing to Disclose, Mark Sulkowski: Nothing to Disclose 705 REGNASE-1 DOWN-REGULATION CONTRIBUTES TO MYELOID CELL INTERMEDIATED ICC DEVELOPMENT Yu Sato 1 Takahiro Kodama 1 Yoshinobu Saito 1 Yuki Tahata 1 Kazuhiro Murai 1 Akira Doi 1 Kumiko Shirai 1 Kazuki Maesaka 1 Hayato Hikita 1 Tomohide Tatsumi 1 Tetsuo Takehara 1 , 1 Osaka University Background: The tumor immune microenvironment (TIME) is a therapeutic target for primary liver cancers
Thus, OIC was successfully established by Loperamide administration
The specific risks typically vary with the materials used
